Scleroderma is a type of connective-tissue disease that causes skin and sometimes internal organs to become hard and tight. In fact, the word scleroderma actually means "hard skin." Scleroderma occurs when the body produces too much collagen, the protein that makes up connective tissues. You can have localized scleroderma, which usually only affects the skin on the hands and face, or systemic scleroderma, which affects connective tissue in many parts of your body, including internal organs. Scleroderma is considered an autoimmune disease, meaning that the immune system mistakenly attacks the body's own tissues. According to the Scleroderma Foundation, about 300,000 people in the United States have the condition.
Symptoms of scleroderma may include the following:
Localized scleroderma
Systemic scleroderma
Scleroderma occurs when the immune system mistakenly attacks the body's own tissues, causing inflammation and an overproduction of collagen. Too much collagen causes the skin, and sometimes the internal organs to become hard and tight. Researchers aren't sure what triggers this autoimmune response, but both genetics and environment may play a role.
The following factors may increase a person's risk for scleroderma:
It isn't always easy to diagnose scleroderma. You may need to see both a rheumatologist (arthritis specialist) and a dermatologist (skin specialist). The doctor will perform a physical examination in which he or she may feel the skin, checking for thickened and hardened areas, and may also press affected tendons and joints. The doctor may also perform the following procedures:
Diagnosing scleroderma may be difficult, particularly in the early stages of the disease. In part, scleroderma is difficult to diagnose because the early symptoms are like those of other connective-tissue diseases, such as rheumatoid arthritis, lupus, and polymyositis. When these conditions overlap, it is called mixed connective-tissue disease.
Although no one knows how to prevent scleroderma, you can take steps to avoid developing infections when you have scleroderma. Your doctor may recommend:
There is no cure for scleroderma. Medication can treat symptoms and may help prevent complications. Lifestyle and dietary changes may make living with the disease easier.
These simple steps may help improve quality of life:
Localized scleroderma often is treated with topical moisturizers or corticosteroids. Oral medications such as minocycline (Minocin or Dynacin) may also be used to halt the progression of localized scleroderma if it involves a large area of the body, such as an entire arm or leg.
Systemic scleroderma may be treated with medications that improve circulation, reduce heartburn, preserve kidney function, and control high blood pressure. Some medications a physician may prescribe for scleroderma include:
When symptoms of scleroderma become very severe, physicians may recommend the following procedures:
A comprehensive treatment plan for scleroderma may include a range of complementary and alternative therapies. People with scleroderma may not get enough vitamins and minerals in their diet, especially if there is damage to their gastrointestinal system. Ask your team of health care providers about the best ways to incorporate these therapies into your overall treatment plan. Always tell your health care provider about the herbs and supplements you are using or considering using.
These general nutritional tips are important for anyone with a chronic disease:
These supplements may help reduce some symptoms:
Herbs are generally a safe way to strengthen and tone the body's systems. As with any therapy, you should work with your health care provider to get your problem diagnosed before starting any treatment. You may use herbs as dried extracts (capsules, powders, teas), glycerites (glycerine extracts), or tinctures (alcohol extracts). Unless otherwise indicated, you should make teas with 1 tsp. herb per cup of hot water. Steep covered 5 - 10 minutes for leaf or flowers, and 10 - 20 minutes for roots. Drink 2 - 4 cups per day. You may use tinctures alone or in combination as noted.
Very few studies have been done using these herbs to treat scleroderma. Ask your doctor before adding any of these herbs to your treatment plan.
A few studies suggest that acupuncture may improve circulation in the hands and fingers, help heal fingertip ulcers, and possibly reduce the formation of fibrous tissue in people with scleroderma. Acupuncture may also lessen pain.
Research suggests that massage may help improve circulation and prevent muscle distortion. More research is needed to determine whether massage is truly an effective therapy for scleroderma.
Biofeedback may help people with scleroderma better control the temperature in their hands and feet. Other mind-body techniques such as counseling, meditation, and emotional freedom technique (EFT) can be very useful.
Possible complications include the following:
The prognosis for people with scleroderma depends primarily on the form of the disease. For example:
Amento EP. Immunologic abnormalities in scleroderma. Semin Cutan Med Surg. 1998;17(1):18-21.
Arlett CM et al Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med. 1998;338(17):1186-91.
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
Beers MH, Porter RS, et al. The Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse Station, NJ: Merck Research Laboratories; 2006:270-272.
Black CM. Scleroderma in children. Adv Exp Med Biol. 1999;455:35-48.
Burckdorfer KR, Hillary JB, Bunce T, et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum. 1995;38(8):1060-1067.
Casale R et al Systemic sclerosis (scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehab. 1997;78(7):767-73.
Cunningham BB, Landells, IDR, Langman C, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211-215.
Elst EF, van Suijlekom-Smit LWA, Oranje AP. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16(1):53-58.
Fauci AS, Braunwald E, Hauser SL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008.
Gelber AC, Wigley FM. Treatment of scleroderma. Curr Opin Rheumatol. 1995;7(6):551-9.
Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol. 2005;5(4):783-93.
Haustein UF, Anderegg U. Pathophysiology of scleroderma: an update. J Eur Acad Dermatol Venereol. 1998;11(1):1-8.
Herrick AL, Worthington H, Rieley F, et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol. 1996;23(4):650-653.
Herrick AL. Advances in palliative care for the patient with scleroderma. Curr Opin Rheumatol. 1996;8(6):555-60.
Herron GS, Romero LI. Vascular abnormalities in scleroderma. Semin Cutan Med Surg. 1998;17(1):12-7.
Hunnicutt SE, Grady J, McNearney TA. Complementary and alternative medicine use was associated with higher perceived physical and mental functioning in early systemic sclerosis. Explore (NY). 2008 Jul-Aug;4(4):259-63.
Hunzelmann N et al. Management of localized scleroderma. Semin Cutan Med Surg. 1998;17(1):34-40.
Jimenez SA et al. Pathogenesis of scleroderma. Rheum Dis Clin North Am. 1996;22(4):647-74.
Kerin K, Yost JH. Advances in the diagnosis and management of scleroderma-related vascular complications. Compr Ther. 1998;24(11-12):574-81.
Maeda M, Kachi H, Ichihashi N et al. The effect of electrical acupuncture-stimulation therapy using thermography and plasma endothelin (ET-1) levels in patients with progressive system sclerosis (PSS). J Dermatol Sci. 1998;17(2):151-155.
Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 1996;22(4):751-64.
Mitchell H, et al. Scleroderma and related conditions. Med Clin North Am. 1997;81(1):129-49.
Olsen NJ, et al. Muscle abnormalities in scleroderma. Rheum Dis Clin North Am. 1996;22(4):783-96.
Pang BK, Munro V, Kossard S. Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. Australas J Dermatol. 1996;37(1):44-47.
Rose S, et al. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998;27(3):563-94.
Silver RM. Scleroderma: clinical problems: the lungs. Rheum Dis Clin North Am. 1996;22(4):825-40.
Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr. 2002;21(6):495-505.
Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996;8(6):569-75.
Skibska B, Jozefowicz-Okonkwo G, Goraca A. Protective effects of early administration of alpha-lipoic acid against lipopolysaccharide-induced plasma lipid peroxidation. Pharmacol Rep. 2006;58(3):399-404.
Van den Hoogen FH, de Jong EM. Clinical aspects of systemic and localized scleroderma. Curr Opin Rheumatol. 1995;7(6):546-50.
Wang HK. The therapeutic potential of flavonoids. Expert Opin Investig Drugs. 2000;9(9):2103-19.
White B. Immunologic aspects of scleroderma. Curr Opin Rheumatol. 1995;7(6):541-5.
Wollina U, Abdel-Naser MB, Mani R. A review of the microcirculation in skin in patients with chronic venous insufficiency: the problem and the evidence available for therapeutic options. Int J Low Extrem Wounds. 2006;5(3):169-80.
Yoon JH, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J. 2005;46(5):585-96.